Prevalence and prognostic role of thoracic lymphadenopathy in Covid-19 = Prävalenz und prognostische Rolle der thorakalen Lymphadenopathie bei Covid-19
Purpose: The prevalent coronavirus disease 2019 (COVID-19) pandemic has spread throughout the world and is considered a serious threat to global health. The prognostic role of thoracic lymphadenopathy in COVID-19 is unclear. The aim of the present meta-analysis was to analyze the prognostic role of...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English German |
| Published: |
2025
|
| In: |
RöFo
Year: 2025, Volume: 197, Issue: 2, Pages: 163-171 |
| ISSN: | 1438-9010 |
| DOI: | 10.1055/a-2293-8132 |
| Online Access: | Resolving-System, lizenzpflichtig: https://doi.org/10.1055/a-2293-8132
|
| Author Notes: | Andreas Michael Bucher, Malte M. Sieren, Felix G. Meinel, Roman Kloeckner, Matthias A. Fink, Marwin-Jonathan Sähn,Andreas Wienke ... [und weitere] |
| Summary: | Purpose: The prevalent coronavirus disease 2019 (COVID-19) pandemic has spread throughout the world and is considered a serious threat to global health. The prognostic role of thoracic lymphadenopathy in COVID-19 is unclear. The aim of the present meta-analysis was to analyze the prognostic role of thoracic lymphadenopathy for the prediction of 30-day mortality in patients with COVID-19. Materials and Methods: The MEDLINE library, Cochrane, and SCOPUS databases were screened for associations between CT-defined features and mortality in COVID-19 patients up to June 2021. In total, 21 studies were included in the present analysis. The quality of the included studies was assessed by the Newcastle-Ottawa Scale. The meta-analysis was performed using RevMan 5.3. Heterogeneity was calculated by means of the inconsistency index I2. DerSimonian and Laird random-effect models with inverse variance weights were performed without any further correction. Results: The included studies comprised 4621 patients. The prevalence of thoracic lymphadenopathy varied between 1% and 73.4%. The pooled prevalence was 16.7%, 95% CI=(15.6%; 17.8%). The hospital mortality was higher in patients with thoracic lymphadenopathy (34.7%) than in patients without (20.0%). The pooled odds ratio for the influence of thoracic lymphadenopathy on mortality was 2.13 (95% CI=[1.80–2.52], p<0.001). Conclusion: The prevalence of thoracic lymphadenopathy in COVID-19 is 16.7%. The presence of thoracic lymphadenopathy is associated with an approximately twofold increase in the risk for hospital mortality in COVID-19. |
|---|---|
| Item Description: | Online veröffentlicht: 22. Juli 2024 |
| Physical Description: | Online Resource |
| ISSN: | 1438-9010 |
| DOI: | 10.1055/a-2293-8132 |